HDAC inhibitors exhibit antitumor activity for multiple myeloma (Song et al., 2011; Santo et al., 2012) and B cell lymphoma (Cortiguera et al., 2019) by suppressing cells survival and differentiation and inducing apoptosis. This evidence concerns the gene HDAC9 and plasma cell myeloma.